Thermally triggered theranostics for pancreatic cancer therapy.

Nanoscale

Institute of Science and Technology in Medicine, School of Pharmacy, Faculty of Medicine and Health Sciences, Keele University, Keele, ST5 5BG, UK.

Published: August 2017

Hybrid iron oxide-gold nanoparticles (HNPs) show the ability to bind drugs onto their surface with a triggered release at elevated temperatures. The iron oxide core allows for diagnostic imaging whilst heating of the gold shell upon laser irradiation reverses drug binding. This study exploits the reversible binding of novel polyamine based drugs in order to provide a specific and effective method for pancreatic cancer treatment. Here we used a novel bisnaphthalamido (BNIP) based drug series. Our hybrid nanoparticles (50 nm) showed the ability to load drugs onto their surface (3 : 1 : 0.25, drug : Fe : Au). By exploiting the surface-to-drug electrostatic interaction of a range of BNIP agents, heat triggered drug release was achieved. A 12-fold reduction in IC after 24 h in vitro and a 5-fold reduction of tumour retardation in vivo compared with free drug in pancreatic models after treatment were achieved with the HNP-formulation and laser irradiation. This heat activated system could provide a key platform for future therapeutic strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c7nr02751fDOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
8
drugs surface
8
laser irradiation
8
thermally triggered
4
triggered theranostics
4
theranostics pancreatic
4
cancer therapy
4
therapy hybrid
4
hybrid iron
4
iron oxide-gold
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!